A survey of more than 1,300 asthma patients found that the majority of respondents (61 percent) had uncontrolled asthma based on their Asthma Control Test (ACT) score, and nearly one-third (29 percent) of those were not aware that their asthma was uncontrolled. Uncontrolled asthma may place patients at risk for increased symptoms, sudden attacks, hospitalization and even death from asthma.
Despite the many advances that have been made over the past 30 years in the prevention, detection, and treatment of cancer, one grim fact remains: the overall five-year lung cancer survival rate is only 15%. The Abramson Cancer Center of the University of Pennsylvania has joined an international effort launched by Roswell Park Cancer Institute to potentially revolutionize the prevention and management of this disease.
New research at Wake Forest University School of Medicine suggests that certain inhaled asthma medications — as well as similar chemicals our bodies produce during times of high stress — may worsen diseases such as asthma, heart failure and lupus that involve inflammation.
Some women experience vaginal itching, burning and other symptoms after sex. They might be allergic to their partner’s semen. According to new research, the extremely rare allergies to seminal fluid can cause symptoms ranging from simple irritation to anaphylactic shock.
In two studies presented during the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI), held in Philadelphia November 9-15, caregivers considered the ?seal of approval? from the FDA to be the most important factor when looking for an effective asthma treatment for their child. Caregivers and physicians also expressed in the study the need for a standardized assessment tool that could help diagnose and monitor asthma.
Newly presented data indicate that treatment with SYMBICORT? (budesonide/formoterol fumarate dihydrate) inhalation aerosol results in significantly greater improvements in lung function, and a lower risk of asthma worsening episodes, compared to budesonide and/or formoterol used alone. In addition, data also showed that SYMBICORT was generally well-tolerated, with an adverse event profile similar to that of its individual components. These study results, involving patients with mild to moderate persistent asthma, were presented today at the American College of Allergy, Asthma & Immunology’s (ACAAI) annual scientific sessions held in Philadelphia on November 9-15, 2006.
Children treated with PULMICORT RESPULES? (budesonide inhalation suspension) either once or twice daily experienced a significantly greater increase in the percentage of asthma-control days compared to those receiving placebo. These results are being presented at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI), held in Philadelphia on November 9-15. Asthma-control days were defined as days when children were free of symptoms and did not use rescue medications during the day and night. Control of asthma symptoms during the day and night and reduction of the need for rescue medication is an important goal of asthma therapy in keeping with current National Asthma Education and Prevention Program (NAEPP) guidelines.
Scientists from the University of Colorado at Boulder and the Centers for Disease Control and Prevention (CDC) have developed an inexpensive “gene chip” test based on a single influenza virus gene that could allow scientists to quickly identify flu viruses, including avian influenza H5N1.
Investigators are presenting more than 380 abstracts on preliminary findings in the diagnosis and treatment of allergic diseases at the ACAAI Annual Meeting in Philadelphia, Nov. 9-15. Following are highlights of some key investigations on allergic rhinitis and ocular allergies.
As the prevalence of allergic rhinitis appears to be rising, there are increasing concerns about its impact on health, sleep, work and school performance, as well as unmet patient needs regarding its treatment according to experts presenting new data at the Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI).